文献速递肝病消化道出血

特纳综合征女性肝病与胃肠道疾病及贫血发生风险增加:全国队列研究

Increased occurrence of liver and gastrointestinal diseases and anaemia in women with Turner syndrome - a nationwide cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2021-02-07

BACKGROUND: Liver and gastrointestinal diseases are frequent in women with Turner syndrome. However, their association with bleeding disorders, anaemia and the impact of hormone replacement therapy is unknown.…

要点

  • 特纳综合征女性肝病风险增加13倍,异常肝酶风险增加12倍。
  • 胃肠道出血、贫血及凝血障碍风险分别增加3.4、3.2及2.9倍。
  • 激素替代治疗未降低胃肠道风险,但对肝病有有益趋势。

核心结论

  • 特纳综合征女性肝病诊断风险高于既往报道,胃肠道出血和贫血发生增加。
  • 激素替代治疗对胃肠道风险无影响,但对肝病有益趋势。

研究设计与样本

  • 数据链接丹麦细胞遗传学中央登记、国家患者登记和药物统计登记,采用负二项回归和分层Cox回归分析。

主要发现

  • 肝病总体IRR 12.9(95%CI 5.8-28.8),其中毒性肝病IRR 8.0(95%CI 1.8-35.4),肝衰竭IRR 6.7(95%CI 1.7-26.9),纤维化/肝硬化IRR 16.5(95%CI 2.2-122.1),未特指肝病IRR 10.6(95%CI 4.4-25.3)。
  • 异常肝酶IRR 12.4(95%CI 4.2-36.6),胃肠道出血IRR 3.4(95%CI 1.8-6.2),贫血IRR 3.2(95%CI 2.0-5.0),凝血障碍IRR 2.9(95%CI 1.1-7.1)。
  • 胃肠道死亡率HR 3.1(95%CI 1.5-6.2),部分死于肝病HR 3.0(95%CI 1.1-8.2)、胃肠道出血HR 29.6(95%CI 3.1-285.1)及毛细血管畸形HR 18.6(95%CI 4.1-85.0)。
  • 这些诊断与炎症性肠病无关。

临床怎么用

  • 对特纳综合征女性应警惕肝病、胃肠道出血及贫血风险,进行相关监测。
  • 激素替代治疗对胃肠道风险无保护作用,但可能对肝病有益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liver and gastrointestinal diseases are frequent in women with Turner syndrome. However, their association with bleeding disorders, anaemia and the impact of hormone replacement therapy is unknown. AIMS: To investigate the risk of liver and gastrointestinal diseases, haemorrhage and anaemia in women with Turner syndrome compared with the female background population, and the long-term impact of hormone replacement therapy on these conditions. METHODS: One thousand one hundred and fifty-six women with Turner syndrome diagnosed during 1960-2014 were identified using the Danish Cytogenetic Central Registry and linked with personal-level data from the National Patient Registry and the Medication Statistics Registry. Statistics Denmark randomly identified 115 577 age-matched female controls. Negative binomial regression was used to analyse hospital discharge diagnoses. Medical prescriptions, mortality and the effect of hormone replacement therapy were estimated using stratified Cox regression. RESULTS: Liver disease increased 13-fold (IRR 12.9 (95% CI 5.8-28.8)), due to toxic liver disease (IRR 8.0 (95% CI 1.8-35.4)), liver insufficiency (IRR 6.7 (95% CI 1.7-26.9)), fibrosis/cirrhosis (IRR 16.5 (95% CI 2.2-122.1)) and unspecified liver disease (IRR 10.6 (95% CI 4.4-25.3)). Furthermore, presence of abnormal liver enzymes increased 12-fold (IRR 12.4 (95% CI 4.2-36.6)). The risk of gastrointestinal haemorrhage (IRR 3.4 (95% CI 1.8-6.2)), anaemia (IRR 3.2 (95% CI 2.0-5.0)) and coagulation disorders (IRR 2.9 (95% CI 1.1-7.1)) was increased. However these diagnoses were not associated with inflammatory bowel disease. Gastrointestinal mortality was increased three-fold (HR 3.1 (95% CI 1.5-6.2)), partly due to death by liver disease (HR 3.0 (95% CI 1.1-8.2)), gastrointestinal haemorrhage (HR 29.6 (95% CI 3.1-285.1)) and capillary malformations (HR 18.6 (95% CI 4.1-85.0)). There was no effect of hormone replacement therapy on gastrointestinal risk but a trend towards a beneficial impact on liver diseases. CONCLUSIONS: The risk of being diagnosed with liver disease was higher than previously reported. The occurrence of gastrointestinal haemorrhage and anaemia was increased in Turner syndrome. There was no effect of hormone replacement therapy on gastrointestinal risk but a trend towards a beneficial impact on liver diseases was detected.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Viuff MH, Stochholm K, Grønbaek H, et al. Increased occurrence of liver and gastrointestinal diseases and anaemia in women with Turner syndrome - a nationwide cohort study. Aliment Pharmacol Ther. 2021. PMID: 33550624. doi:10.1111/apt.16277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。